Los Angeles Capital Management LLC lowered its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 19.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 164,327 shares of the company's stock after selling 40,707 shares during the period. Los Angeles Capital Management LLC owned about 0.53% of Medpace worth $54,852,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Private Advisor Group LLC grew its holdings in Medpace by 10.1% during the 1st quarter. Private Advisor Group LLC now owns 1,065 shares of the company's stock valued at $430,000 after buying an additional 98 shares during the last quarter. Janney Montgomery Scott LLC raised its stake in Medpace by 7.5% in the 1st quarter. Janney Montgomery Scott LLC now owns 7,630 shares of the company's stock valued at $3,084,000 after purchasing an additional 532 shares during the last quarter. SG Americas Securities LLC raised its stake in Medpace by 351.5% in the 1st quarter. SG Americas Securities LLC now owns 15,002 shares of the company's stock valued at $6,063,000 after purchasing an additional 11,679 shares during the last quarter. Swiss National Bank lifted its holdings in Medpace by 0.4% in the 1st quarter. Swiss National Bank now owns 48,400 shares of the company's stock valued at $19,561,000 after purchasing an additional 200 shares in the last quarter. Finally, Sei Investments Co. boosted its stake in shares of Medpace by 12.7% during the 1st quarter. Sei Investments Co. now owns 135,649 shares of the company's stock worth $54,822,000 after purchasing an additional 15,304 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.
Medpace Price Performance
Medpace stock traded up $9.37 during midday trading on Friday, hitting $362.79. 358,083 shares of the company were exchanged, compared to its average volume of 409,613. Medpace Holdings, Inc. has a fifty-two week low of $268.80 and a fifty-two week high of $459.77. The company's fifty day moving average price is $341.59 and its 200-day moving average price is $377.29. The company has a market cap of $11.28 billion, a PE ratio of 31.77, a price-to-earnings-growth ratio of 1.98 and a beta of 1.37.
Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, beating analysts' consensus estimates of $2.77 by $0.24. The firm had revenue of $533.32 million during the quarter, compared to analyst estimates of $540.99 million. Medpace had a return on equity of 50.87% and a net margin of 17.66%. Medpace's quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter last year, the firm earned $2.22 EPS. On average, analysts expect that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.
Analyst Ratings Changes
Several brokerages recently issued reports on MEDP. Truist Financial reduced their price objective on shares of Medpace from $415.00 to $397.00 and set a "hold" rating on the stock in a research note on Monday, October 14th. UBS Group cut Medpace from a "buy" rating to a "neutral" rating and decreased their price objective for the stock from $420.00 to $350.00 in a report on Friday, September 27th. TD Cowen lowered their price objective on Medpace from $413.00 to $372.00 and set a "buy" rating for the company in a research report on Wednesday, October 23rd. Deutsche Bank Aktiengesellschaft reduced their target price on Medpace from $395.00 to $336.00 and set a "hold" rating on the stock in a research report on Wednesday, July 24th. Finally, William Blair restated an "outperform" rating on shares of Medpace in a report on Tuesday, October 22nd. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $380.00.
Check Out Our Latest Research Report on Medpace
Medpace Company Profile
(
Free Report)
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
See Also
Before you consider Medpace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.
While Medpace currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
